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Aims/Hypothesis. It was suggested that polyunsaturated n-3
fatty acids (n-3 PUFAs) could improve insulin sensitivity and
have an anti-inflammatory effects in overall population. This study
investigates a possible effect of n-3 PUFAs supplementation on the
insulin sensitivity and some inflammatory markers; hence, patients
with chronic renal failure (CRF) on maintenance hemodialysis
(MHD) are presented with insulin resistance. Methods. This
study explored the ratio between red blood cells (RBC) phospho-
lipid long chain fatty acids (LC FAs) and components of meta-
bolic syndrome (MeS) in 35 patients (mean age 54.50 ± 11.99
years) with CRF on MHD. Furthermore, the effects of omega-3
FA eight-week’s supplementation (EPA+DHA, 2.4g/d) on the
MeS features and inflammatory markers TNF-alpha, IL 6, and
hsCRP were examined. Results. Supplementation increased EPA
and DHA levels in RBCs (p = 0.009 for EPA and p = 0.002 for
DHA). Total n-6 PUFAs: n-3 PUFAs ratio tended to be lower
after supplementation (p = 0.31), but not significantly. Data
revealed a significant decrease of saturated FAs (SFA) (p = 0.01)
as well as total SFA: n-3 PUFAs ratio during the treatment (p =
0.04). The values of serum insulin and calculated IR index-IR
HOMA were reduced after supplementation (p = 0.001 for both).
There was a significant decrease in the levels of all inflammatory
markers (p = 0.01 for TNF alpha, p = 0.001 for IL 6, p = 0.001
for hsCRP, and p = 0.01 for ferritin). In multivariate regression
analysis, only the changes in n-6 PUFAs: n-3 PUFAs ratio inde-
pendently contributed to 40% of the variance in IR HOMA. The
impact of changes in PUFAs level in RBCs membrane phospho-
lipid fatty acids on inflammation markers was also registered.
The changes in n-6: n-3 PUFAs ratio independently contributed
to 18% of the variance in TNF alpha. Conclusion. It was con-
cluded that the EPA and DHA moderate dose administration in
the patients with CRF on MHD had a beneficial effect on insulin
resistance decrease. The anti-inflammatory effects of the supple-
mented PUFAs were also presented.
Keywords end-stage renal disease, insulin resistance, n-6
PUFAs, n-3 PUFAs, inflammatory marker TNF-
alpha
INTRODUCTION
Patients with chronic renal failure (CRF) on mainte-
nance hemodialysis (MHD) exhibit plasma fatty acid
patterns similar to those with nutritional deficiency of
essential fatty acids,[1] as well as limited storage of the n–3
fatty acids in adipose tissue, like those in the healthy
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population.[2] This suggestion implied a continued dietary
supply. Experimental and in vitro studies have showed
that n-3 fatty acids such as -linolenic acid (ALA), fish oil,
eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA) have anti-inflammatory,[3] antithrombotic,[4] and
antiarrhythmic properties[5–7] and improve insulin sensi-
tivity.[8] In a prospective study of healthy males, low base-
line total n-3 fatty acid, EPA, and DHA levels in the blood
are associated with a greater risk of sudden death.[6] In
contrast, n-6 fatty acids such as linoleic (LA) and arachi-
donic acid (AA) have even been reported to promote
inflammation, thrombosis, and insulin resistance.[9] Stor-
lien et al. showed that high skeletal muscle membrane n–6
PUFA: n–3 PUFA ratio was inversely related to insulin
sensitivity.[10]
The high prevalence of insulin resistance and dyslipi-
demia, the components of metabolic syndrome among
CRF patients on HD,[11,12] and a significant negative cor-
relation between calculated IR and the level of ALA in
plasma phospholipids were found.[13] Furthermore, signifi-
cantly lower levels of EPA, DHA, and total n-3 PUFAs in
erythrocyte phospholipid fatty acids were found in such
patients.[14] In agreement with that finding, the beneficial
effects of moderate n–3 PUFA (EPA and DHA) supple-




Forty-two patients were recruited from the HD Unit
of Zemun Clinical Hospital. Patients were regularly dia-
lyzed for more than 12 [89 ± 66] months. Seven patients
were dropped out because of intercurrent illness (three
patients), dialysis centers change (two patients), and some
personal settings (two patients). Exclusion criteria were
diabetes mellitus, heart failure (NYHA III or IV), acute
myocardial infarction, and acute infectious disorders
within three months of the inclusion. Patients were not
obese and with no severe malnutrition (BMI 20–30 kg/m2).
Patients were dialyzed with synthetic membranes and a
bicarbonate dialysate with 1.25, 1.5, or 1.75 mmol/L cal-
cium according to the serum calcium–phosphate equilib-
rium and with obligatory use of 1,25-dihydroxy vitamin
D3 [1,25(OH)2D3] to control the parathyroid hormone
(PTH) levels. The duration of HD was individually tai-
lored (4–6 h weekly) to control body fluids and blood
chemistries with the aim to achieve Kt/V > 1.2 (1.46 ±
0.13). Patients did not regularly receive epoetin therapy
during that time. Antihypertensives were prescribed when
it was necessary to obtain pre-dialysis blood pressure
<160/90 mmHg. None of the patients received lipid-low-
ering drugs, beta-blockers, l-carnitine, or vitamin B12 three
months before the inclusion. Patients regularly took iron
and vitamin supplements. Calcium carbonate (CaCO3)
was used to obtain pre-dialysis serum phosphate level
<2.0mmol/L. All patients were sedentary (<1 h/wk of
physical activity), free of alcohol consumption, and non-
smokers. They maintained their habitual diets (35 kcal/kg
BW, protein intake 1.0–1.2g/kg BW, fats <35% caloric
intake) with sodium and potassium restriction. They had
low habitual consumption of foods containing soy, fish
intake once a week, and no dietary supplementation of oil
rich in long-chain fatty acids, as determined by diet assess-
ment made at the time of recruitment. Each patient gave
informed written consent to participate in the study, which
was approved by the Institutional Ethic Committee.
Study Design
This study was a cross-sectional and follow-up
dietary intervention study. The patients continued to con-
sume high (corn oil-based) n-6 PUFA cooking oils as part
of their usual diet, with daily supplementation of n-3 LC
PUFA [2.4g EPA+DHA;2:1 EPA/DHA ratio (Natural
Wealth Company)] for the eight weeks of the study. N-3
PUFAs were administered in capsules of fish oil supple-
mented with EPA+DHA (the ratio was 2:1), 2.4g per day,
once weekly. The diet control was done as usual for all
study participants by interview during HD. The CRF
patients were dialyzed three times weekly in the HD unit.
The blood samples were taken to determine the red
blood cell phospholipid fatty acids composition before the
beginning and at the end of the eight-week n-3 LC-PUFA
supplementation period. The fasting blood lipids, glucose,
insulin, ionized calcium, serum phosphates, albumin,
hemoglobin, iron, ferritin, high sensitivity C-reactive pro-
tein (hsCRP), TNF-alpha, and IL-6 were assessed from the
same blood samples with a conventional autoanalyzer.
Blood samples were taken in the middle of week, after
12–14h of overnight fasting and immediately prior to dial-
ysis. Fasting insulin and glucose concentrations were used
to calculate insulin resistance from the IR-HOMA model
(insulin0 × glucose0/22.5).[15]
Biochemical Analysis
Plasma triglyceride, glucose, and total cholesterol
concentrations were measured by using standard enzyme
color tests (Diagnostics ELITECH, Paris, France); HDL
cholesterol was determined by the enzyme procedure, after
precipitation by the phosphotungstic acid, in supernatant
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on the Technicon –RA 1000 analyzer; and insulin level
was measured using the radioimmunoassay method (INEP
Zemun, Belgrade, Serbia). Ferritin was measured by a tur-
bidimetric fixed rate method (Olympus System Reagent;
Olympus Diagnostica, Hamburg, Germany). Serum iron
was measured by a photometric color test for clinical
chemistry analyzers (Olympus System Reagent; Olympus
Diagnostica). IL-6 and TNF-alpha concentrations were
measured in duplicate by Immunotech IL-6 immunoassays
and Immunotech TNF-alpha immunoassays (Beckman
Coulter™, Fullerton, California, USA), and hsCRP was
measured by the Olympus (LATEX) assay on the Olympus
AU 400 analyzer (Olympus, Pennsylvania, USA). Blood
samples for human cytokine determination (human IL-6 and
human-TNF-alpha) were allowed to clot for 30 minutes
before centrifugation for 15 minutes at 1000 g, and serum
was removed rapidly and carefully from clot. Serum sam-
ples were stored in plastic tubes at −70°C until analysis
(no longer than one month). Human IL-6 concentrations
were measured in duplicate by Immunotech IL-6 immuno-
assays (IM1120, IM11120) (Beckman Counter™) in
serum samples. This ELISA is a one immunological step
sandwich-type assay. Samples and standards were incubated
in the microtiter plate coated with the first monoclonal
antibody anti-IL-6, in the presence of the second anti-IL-6
monoclonal antibody linked to acetylcholinesterase. After
incubation, the wells are washed and the bound enzymatic
activity is detected by addition of a chromogenic substrate.
The intensity of the coloration is proportional to the IL-6
concentration in the sample or standard.
Human TNF-alpha concentrations were measured in
duplicate by Immunotech TNF-alpha immunoassays
(IM1121, IM11121) (Beckman CounterTM) in serum sam-
ples. This ELISA test is one-immunological step sandwich-
type assay. Samples and standards were incubated in the
microtiter plate coated with the first monoclonal antibody
anti-TNF-alpha, in the presence of the second anti-TNF-
alpha monoclonal antibody linked to alkaline phosphatase.
After incubation, the wells are washed, and the bound enzy-
matic activity is detected by addition of a chromogenic sub-
strate. The intensity of the coloration is proportional to the
IL-6 concentration in the sample or standard.
Determination of Red Blood Cell Fatty Acids
N-6 and n-3 PUFAs content was determined in cell
membrane of erythrocytes by gas-liquid chromatography
(GC). Total lipids from erythrocyte membranes were
extracted, and then free fatty acids separated according to
Kates.[16] GC determined the total fatty acid composition
in the methyl esters form. Fatty acid methyl esters form
were prepared using BF3-methanol solution and extracted
with hexane.[17] GC analysis was performed on a VARIAN
chromatograph, Model 1400, equipped with a flame ion-
ization detector and a 30m × 0.32 cm steel column, packed
with LAC-3R-728 (20%) on Chromosorb W/AW (80–100
mesh). Nitrogen was used as a carrier gas (flow rate
24mL/min). The GC oven temperature was kept on 180°C.
The detector and injector temperature was 200°. GC anal-
ysis was performed according to the International Standards.
Fatty acids were identified by comparison with retention
times (Rt) of standards (Supelco TM Fame Mix). Relative
content of each fatty acid was calculated from the ratio of
the relevant peak area to the total peak area, and the results
were expressed as percentage of total identified phospho-
lipid fatty acids.
Statistical Analysis
Statistical analyses were performed with the SSPS sta-
tistical package (SPSS, Chicago, Illinois, USA). Signifi-
cance was accepted at the level of p < 0.05. Before
statistically analyzed, all data were examined for normality
by using the Shapiro-Wilks test. Differences in the absolute
changes in fasting plasma triglycerides, total cholesterol,
HDL cholesterol, hs-CRP, TNF-alpha, IL-6, glucose, insu-
lin, iron and ferritin concentrations, and calculated IR-
HOMA over the eight-week period of fish-oil supplementa-
tion were determined using independent-sample t tests or
Kruskal-Wallis test for variables with skewed distribution.
Results are presented as group means ( ± SDs), or median
(interquartiles range). Changes in erythrocyte membrane
phospholipid fatty acids composition were assessed by using
independent-sample t tests or Kruskal-Wallis test. Variables
with a skewed distribution (serum insulin, IR HOMA,
inflammatory cytokines, iron, ferritin, and some PUFAs)
were naturally log transformed for analyses involving con-
tinuous variables. Covariates with missing values were
assigned the group mean.
RESULTS
The baseline characteristics of the 35 MHD patients
who completed the study are presented in Table 1. There
were no significant differences in the anthropometrical
characteristics of MHD patients before and after eight
weeks of fish oil supplementation. A significant decrease
of the insulin, calculated IR HOMA, inflammatory marker
[TNF-alpha, IL-6, hs-CRP] and ferritin levels (p < 0.01
for all mentioned variables) were observed after dietary
intervention regime. Its influence on fasting plasma trig-
lyceride, total cholesterol, and serum iron levels were not
significant (p > 0.05).
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Erythrocyte Membrane Phospholipid Fatty Acids 
Composition before and after Fish-Oil 
Supplementation
Fish-oil supplementation over eight weeks resulted in
significant changes of some erythrocyte phospholipid fatty
acids composition, as presented in Table 2. The significant
increase of n-3 PUFAs, ALA EPA, and DHA (p < 0.01)
was obtained at the end of study period, as well as signifi-
cant increase of some n-6 PUFAs, LA (p = 0.02), gamma
linolenic acid, and AA (p < 0.01). Furthermore, total n-3
and n-6 PUFAs were not significantly increased after sup-
plementation (p < 0.01). Total SFA and SFA: n-3 PUFA
ratio significantly decreased after supplementation period
(p < 0.05), which was not observed with n–6 PUFAs: n-3
PUFAs ratio (p > 0.05).
A low level of EPA independently accounted for 34%
of the variance in IR HOMA in the pretreatment period
(see Table 3). The levels of baseline hs-CRP inversely cor-
related with n-3 PUFAs (r=-0.39, 0.01 < p < 0.05), oppo-
site to the levels of TNF-alpha, which were positively
correlated with n-6 PUFAs: n-3 PUFAs ratio before the
supplementation (r=0.420, p = 0.03).
The reduced total n–6 PUFAs: n-3 PUFAs ratio
correlated with an IR HOMA reduction (r= 0.369, 0.01
< p < 0.05), an increase of HDL cholesterol (r=0.392, 0.01
< p < 0.05), as well as a decrease of TNF-alpha
(r=0.420, 0.01 < p < 0.05) after the supplementation
period. In multivariate regression analysis, only changes
in n-6 PUFAs: n-3 PUFAs ratio associated with changes
in AA and serum iron contributed to 40% of the variance
in IR HOMA (see Table 4). In addition, significant corre-
lations between the changes in TNF-alpha and n-6
PUFAs: n-3 PUFAs ratio, AA and MUFAs levels (0.01 <
p < 0.05) were registered. In multivariate regression
analysis, only changes in n-6 PUFAs: n-3 PUFAs ratio
independently contributed to 18% of the variance in TNF
alpha (see Table 5).
DISCUSSION
N-6 PUFAs are predominant PUFA in all diets. When
the diet is supplemented with n-3 PUFAs, the latter par-
tially replace n-6 PUFAs in the vast majority of the cell’s
membranes (e.g., erythrocytes, platelets, monocytes, lym-
phocytes, granulocytes, endothelial cells, neuronal cells,
colon cells, and hepatic cells). Competition between n-6
PUFAs and n-3 PUFAs occurs in prostaglandin formation.
EPA competes with AA for prostaglandin and leukotriene
synthesis at cyclooxygenase and lipoxygenase level.
5-lipoxygenase activity and expression are significantly
increased in periferal blood mononuclear cells (PBMCs)
of ESRD patients on maintenance HD.[18] Taccone-
Gallucci et al. reported dose-dependent inhibition of
5-lipoxygenase activity after three months of supplemen-
tation with omega-3 in daily dose of 2.7g EPA+DHA,
with reduced lipid peroxidation and LTB4 synthesis.[18]
Table 1 
The baseline characteristics of study participants and responsiveness to fish oil supplementation after eight weeks
Variable Before supplementation After supplementation Significance*
Age (years) 54.5 ± 12
Gender (male/female) 20/15 (54.3%/ 45.7%)
Hemodialysis duration (months) 48 (24–82)
Body mass index (kg/m2) 22.17 ± 2.99 22.31 ± 2.86 0.93
Waist (cm) 86.47 ± 9.90 85.65 ± 8.40 0.86
Triglycerides (mmol/L) 2.30 ± 0.68 2.19 ± 0. 88 0.21
Total cholesterol (mmol/L) 5.31 ± 1.13 4.90 ± 1.02 0.84
HDL cholesterol (mmol/L) 0.91 ± 0.14 1.14 ± 0.17 0.08
Glucose (mmol/L) 5.31 ± 0.90 4.94 ± 0.79 0.51
Insulin (mU/L) 35.25 (26.90–59.20) 17.6 (14.40–27.90) 0.001†
IR HOMA 8.67 (6.01–15.30) 3.55 (2.77–6.97) 0.001†
hs-CRP (mg/L) 24.6 (19.7–30.5) 3.7 (1.4–10.9) 0.001†
TNFalpha (pg/ml) 2.08 (0.99–2.82) 0.45 (0.23–0.71) 0.01†
IL-6 (pg/ml) 1.60 (1.16–8.04) 0.30 (0.17–0.78) 0.001†
Iron (μg/L) 13.15 (6.9–17.9) 20.6 (9.9–27.0) 0.23†
Ferritin (μg/L) 462.0 (262.0–807.2) 310.9 (164.5–382.8) 0.01†
Values are mean ± SD or median (interquartile range).
*Independent sample t test or †Kruskal-Wallis test for skewed variables.
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In the present study, the supplementation of LC n-3
PUFAs (EPA+DHA) with relatively high dietary intake of
n-6 PUFAs is in the concordance with the hypothesis that
fatty acid composition of membrane phospolipids was
related to insulin resistance. Also, an improvement of
insulin resistance was directly related to the reduction of
total n-6 PUFAs: n-3 PUFAs ratio.[8,19] There is clear evi-
dence of altered insulin binding and its action as a result of
modification of fatty acids in the membrane phospolip-
ids.[10] Min et al. showed that gestational diabetes was
associated with AA and DHA reduction and increased
palmitic acid in the red cell phosphoglycerides.[20] The
biosynthesis of AA and DHA requires delta-6 and delta-5
Table 2 
Erythrocyte phospholipid fatty acids composition before and after eight weeks of fish oil supplementation in HD patients
Fatty acid (% of total) Before supplementation After supplementation Significance*
14:0 1.18 ± 0.48 0.56 ± 0.32 0.007
15:0 0.58 (0.35–0.62) 0.21 (0.10–0.42) 0.001†
16:0 29.93 ± 3.52 28.30 ± 3.70 0.04
18:0 13.58 ± 2.03 12.28 ± 3.85 0.002
16:1 (n-7) 0.78 ± 0.36 1.06 ± 0.75 0.001
18:1 (n-9) 23.96 ± 2.76 23.90 ± 3.55 0.07
18:2 (n-6) 12.17 (9.98–13.16) 15.80 (13.80–17.70) 0.02†
18:3 (n-3) 0.18 ± 0.13 0.30 ± 0.18 0.01
18:3 (n-6) 0.10 (0.0–0.17) 0.19 (0.13–0.28) 0.01†
20:3 (n-6) 1.91 ± 0.54 2.58 ± 1.10 0.03
20:4 (n-6) 7.44 ± 1.14 8.18 ± 2.70 0.001
20:5 (n-3) 0.21 (0.04–0.34) 0.30 (0.18–0.60) 0.009†
22:4 (n-6) 0.45 ± 0.10 0.35 ± 0.17 0.02
22:5 (n-3) 0.63 ± 0.42 0.64 ± 0.51 0.19
22:6 (n-3) 1.97 ± 0.69 (1.91[1.56–2.27]) 2.53 ± 0.81(2.44[2.0–3.0]) 0.37 (p = 0.002)†
PUFA (n-6) 20.28 ± 3.15 24.65 ± 3.58 0.29
PUFA (n-3) 3.07 ± 0.81 4.00 ± 0.97 0.23
PUFA (n-6): (n-3) 7.15 ± 2.580 6.52 ± 1.87 0.31
MUFA 24.74 ± 2.76 24.96 ± 3.38 0.07
SFA 45.33 ± 3.14 41.47 ± 4.45 0.01
SFA:n-3 PUFA 15.21 ± 4.51 10.79 ± 3.11 0.04
Values are mean ± SD or median (interquartile range). Abbreviations: PUFA=polyunsaturated fatty acids, MUFA=mono-unsaturated
fatty acids, SFA=saturated fatty acids.
*Independent sample t test or †Kruskal-Wallis test for skewed variables.
Table 3 
Multiple linear regression analysis equations in 







Multiple linear regression analysis equations in HD patients (IR 
HOMA and fatty acids) after fish oil supplementation
Variable Beta Significance
Δ n-6 PUFA/ n-3 PUFA 0.675 0.002
Δ AA 0.301 0.10
Δ iron 0.150 0.32
Adjusted R2=0.40.
Table 5 
Multiple linear regression analysis equations in HD patients 
(TNF alpha and fatty acids) after fish oil supplementation
Variable Beta Significance
Δ n-6 PUFA/ n-3 PUFA 0.331 0.03
Δ MUFA 0.263 0.16
Adjusted R2=0.18.
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desaturase that are insulin-dependent. However, it is con-
ceivable that their function could be depressed as in Type
2 DM and obesity.[21] Furthermore, increases of AA and
DHA levels in HD patients could be a consequence of
repaired insulin sensitivity during supplementation period.
The present results are in accordance with the study of
Pischon et al.,[22] who explained that high intake of n-6
PUFAs did not antagonize anti-inflammatory effects on
n-3 PUFAs. Furthermore, n-6 PUFAs lower the levels of
soluble TNF receptors indirectly by reducing insulin resis-
tance. However, many human trials confirmed that high
intake of n-3 and n-6 PUFAs could inhibit the activity of
the cyclooxygenase and reduce inflammatory media-
tors.[23] PUFAs may also modulate cytokine production
through eicosanoid-independent pathways by influencing
membrane composition and fluidity, affecting signal trans-
duction processes or binding to or affecting nuclear recep-
tors such as PPARs or nuclear factor-kB.[24] Observational
data suggested that dietary fish oil and ALA are inversely
correlated with CRP levels. Caughey et al. demonstrate
that a diet enriched with flaxseed oil could inhibit the ex
vivo production of inflammatory cytokines IL-1 beta and
TNF-alpha by 30% in four weeks, whereas nine grams of
fish oil for another four weeks inhibited IL-1beta by 80%
and TNF-alpha by 74%.[25] In the study of Endres, IL-1beta,
IL-1alpha, and TNF-alpha were decreased for 42% at six
weeks, but a further decrease was observed after 10 weeks
after the discontinuation of treatment with fish oil. There-
fore, fish oil probably induces suppression of IL-1, con-
tributing to the amelioration of clinical signs and
symptoms of disease activity in patients of rheumatoid
arthritis to a greater extent than does inhibition of leukot-
riene metabolism.[26]
It was shown in the experimental model that the treat-
ment of diabetic Goto-Kakizaki rats with AA and zinc
resulted in insulin resistance improvement.[27] As was
published previously, RBCs membrane phospholipid fatty
acids composition in HD patients is altered, with signifi-
cantly lower levels of EPA, DHA, and total n-3 PUFAs
comparedto those in control subjects.[14] Friedman et al.
recently suggested that HD patients be at risk for inade-
quate n-3 fatty acids intake and, consequently, its lowered
blood levels.[28] It was shown here that low levels of n-3
fatty acids were replaced by higher levels of palmitic and
oleic acids. A significant correlation between erythrocyte
membrane phospholipid fatty acids composition and cal-
culated IR HOMA was estimated, particularly for the ratio
of SFA to n-3 PUFA, EPA, and for AA before supplemen-
tation with n-3 PUFAs. However, after eight weeks of sup-
plementation only n-6 PUFAs: n-3 PUFAs ratio
independently predicted insulin resistance improvement.
According to the study conducted in non-HD patients, the
imbalance in dietary n–6 PUFAs: n–3 PUFAs could play a
significant role in insulin sensitivity, thereby affecting
insulin-sensitive components, such as plasma triacylglyc-
erol.[29] Fiedler et al. carried out the study with lower
doses of n-3 PUFAs (1.2g/d) in MHD patients, and levels
of triglycerides and very-low-density lipoproteins were
decreased after 12 weeks of supplementation; however,
the high level of homocystein persisted. The authors sup-
posed that only high doses of omega-3 fatty acids given
for a longer period had influenced inflammation and
atherosclerosis.[30]
A significant increase in EPA and DHA as well as a
significant decrease of SFAs percentage in membrane
phospholipids was registered in our HD patients after the
eight weeks of supplementation. Also, a significant
increase in total n-3 PUFAs and n-6 PUFAs was noted.
The n-6 PUFA: n-3 PUFA ratio was not significantly
modified, despite its tendency to become lower. The
increased levels of the erythrocyte phospholipid’s n-6
PUFAs (18:2, 18:3, 20:3, 20:4) after supplementation
could be explained via ordinary diet changes (against our
recommendations, the patients made an effort to have
“healthy” diet with more fruits, whole grains, and vegeta-
bles). That probably was the reason of 18:3n-3 (ALA)
increase. A lower increase of 22:6n-3 (DHA) is likely to
be a consequence of short-term supplementation, and
DHA has not been sufficiently incorporated in erythrocyte
membrane phospoholipids because less time is needed for
its incorporation than for EPA. However, shortened red
blood cell life span as one of the renal anemia features,
with the mean half-life 22–27 days,[31] determined the
duration of treatment after eight weeks to see the effects.
In this study, a significantly reduced level of SFAs
probably prevented deleterious effects of both palmitic acid
and elevated blood glucose levels on pancreatic beta-cells
function. This is in agreement with the previous reports, in
which the formation of ceramide and activation of the apop-
totic mitochondrial pathway, which was given up by oleic
acid,[32] explained the deleterious effects of palmitic acid.
Summers et al. reported that the substitution of dietary SFA
with PUFAs improved insulin sensitivity but with changes
in distribution of abdominal fat.[33] An increasing body of
evidence suggests that supplements of n–3 marine FAs may
improve defects in insulin signaling and prevent alterations
in glucose homeostasis and further development of type 2
diabetes. These effects are likely mediated through the per-
oxisome proliferator-activated receptors (PPARs), which
are up-regulated by polyunsaturated C20 and C22 fatty
acids, including EPA and DHA, and in turn are related to
the gene expression involved in lipid oxidation and synthe-
sis.[34] Other, pleiotrophic effects of n–3 PUFAs may con-
tribute to decrease the burden of the metabolic syndrome,
such as the modulation of inflammation, platelet activation,
endothelial function, and blood pressure.[35]
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It was shown here that changes in the n-6 PUFAs: n-3
PUFAs ratio independently contributed to 40% of the vari-
ance in IR HOMA of MHD patients. Increased n–6
PUFAs did not attenuate the effects of long-chain n–3
PUFAs on insulin sensitivity, as the n-6 PUFAs: n-3
PUFAs ratio tended to be lower than before supplementa-
tion, something Brady et al. showed in healthy subjects.[36]
Minor changes of AA in multivariate modeling did not
significantly influence on the insulin resistance. Other
parameters of metabolic syndrome, such as levels of triglyc-
eride and HDL cholesterol, did not change significantly.
However, the change of HDL cholesterol was associated
with a decrease of n-6 PUFAs: n-3 PUFAs ratio.
It is well established that patients with CRF on MHD
are often malnourished, with the presence of chronic
inflammation and higher level of pro-inflammatory biom-
arkers.[37] Although various factors related to the dialysis
procedure may contribute to inflammation in ESRD, a
number of non-dialysis-related factors are also important.
As only non-overweight subjects were recruited, the
impact of obesity on the presence of inflammation was
excluded. However, inflammation and protein energy mal-
nutrition are closely related to each other in dialysis
patients and appear to play a central role in poor clinical
outcome.[38] Berstad et al. have investigated the effect of
fish oil supplementation on atherosclerotic activity and
found that a large increase in serum EPA and especially
DHA might increase inflammation in vascular endothe-
lium through an increase in the level of sVCAM-1.[39] The
same authors also noted that there was no significant inter-
action between the dietary intervention and n-3 PUFAs
supplementation. On the other hand, a moderate dietary
intake in healthy human volunteers with fish oil-derived
n-3 PUFA results in a decrease of monocyte and neutrophil
chemotaxis as well as production of proinflammatory
cytokines.[40] N-3 PUFA incorporation into an olive oil
diet significantly decreased colonic TNF and LTB4 levels
compared with colitic rats that were not supplemented
with fish.[41] These n-3 PUFAs (EPA and DHA) induce
PGE3 and LTB5 production, with lower potency as pro-
inflammatory mediators.[41] The level of TNF-alpha in the
colon of rats was almost four-fold lower after supplemen-
tation. The findings that plasma FAs composition is linked
to inflammatory activity in subjects with insulin resis-
tance[42] suggest possible associations in MHD patients.
However, the current study identified only a strong associ-
ation between changes in n-6 PUFAs: n-3 PUFAs ratio
and TNF-alpha levels after supplementation with n-3
PUFAs. As is already known, TNF-alpha impairs insulin
signaling by inhibiting the function of IRS-1 through serin
phosphorylation, and one could speculate that n-6 to n-3
PUFAs ratio could also modify insulin resistance indi-
rectly, through TNF-alpha. In addition, reduced ferritin
level after supplementation according to the finding that ele-
vated ferritin level in patients with metabolic syndrome and
CRF are mainly due to inflammatory mechanisms rather
than to iron overload.[36,43] It seems that moderate n–3 LC-
PUFA supplementation over the eight-week period directly
and indirectly affected insulin resistance in HD patients.
The ratio n-6 to n-3 PUFAs was crucial for the reduction of
insulin resistance in our non-obese and only moderately
malnourished MHD patients. Limited positive effects on
inflammatory markers—especially on TNF-alpha, which
participate in metabolic syndrome as adipokine—were also
noticed. One can speculate that a higher dose and longer
period of n-3 PUFAs supplementation can promote a higher
increase in erythrocyte membrane phospholipid fatty acids,
EPA and DHA, and consequently could be suitable for an
improvement of metabolic syndrome.
In conclusion, supplementation with n-3 LC PUFAs
in HD patients is useful in regard to the reduction of insu-
lin resistance and TNF-alpha levels, which is associated
with changes in the n-6: n-3 PUFAs ratio.
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